This trial is basically led by my mentor Dr Rana McKay at UCSD, which I presented this morning as a poster over here as well. So radium-223, an alpha-emitting radioisotope, it increases, it has shown its impact in bone metastasis as well. Dr McKay had previously led some studies in metastatic prostate cancer as well, where with radium-223, with some other additional agents, it showed that particularly for osseous metastasis or bone mets, the outcomes were really good...
This trial is basically led by my mentor Dr Rana McKay at UCSD, which I presented this morning as a poster over here as well. So radium-223, an alpha-emitting radioisotope, it increases, it has shown its impact in bone metastasis as well. Dr McKay had previously led some studies in metastatic prostate cancer as well, where with radium-223, with some other additional agents, it showed that particularly for osseous metastasis or bone mets, the outcomes were really good. There was a pilot study which showed that with cabozantinib’s impact on VEGF, but along with different TKIs, it potentiates the impact of alpha-emitting radium-223, the alpha-emitting radioisotope. And based on this, the skeletal events or SSEs would be reduced. The pilot study showed that the bone turnovers, bone markers went down. It also showed it was safe and efficacy was good as well, so based on those previous studies in the pilot study, we are working on this current Phase II study. It’s already enrolling, it’s still open for enrollment as well, and we are hoping to have really good results coming out soon.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
